ACTIV trials: Lessons learned in trial design in the setting of an emergent pandemic

By sjmartinez • October 31, 2024

Keshtkar-Jahromi M, Anstrom KJ, Barkauskas C, Brown SM, Daar ES, Fischer W, Gibbs KW, Higgs ES, Hughes MD, Jagannathan P, LaVange L, Lindsell CJ, Nayak SU, Paredes R, Parmar M, Peltan ID, Proschan M, Shotwell MS, Vock DM, Yokum T, Adam SJ. ACTIV trials: Lessons learned in trial design in the setting of an emergent pandemic. J Clin Transl Sci. 2024 Oct 15;8(1):e151. doi: 10.1017/cts.2024.1. PMID: 39478775; PMCID: PMC11523015.

Tags: ACTIV, Clinical Trial, covid-19, design, Infectious Diseases, lessons, Publications

Host-microbe multiomic profiling identifies distinct COVID-19 immune dysregulation in solid organ transplant recipients

Pickering H, Schaenman J, Phan HV, Maguire C, Tsitsiklis A, Rouphael N, Higuita NIA, Atkinson MA, Brakenridge S, Fung M, Messer W; IMPACC Network; Salehi-Rad[...]

MicroRNA Biomarkers and Host Response Pathways in Severe Pulmonary Hemorrhagic Syndrome due to Leptospirosis: A Multi-Omics Study

Tran PNT, Limothai U, Dinhuzen J, Tachaboon S, Sukmark T, Dokpong C, Roytrakul S, Haake DA, Srisawat N. MicroRNA Biomarkers and Host Response Pathways in[...]

Clade I mpox virus genomic diversity in the Democratic Republic of the Congo, 2018-2024: Predominance of zoonotic transmission

Kinganda-Lusamaki E, Amuri-Aziza A, Fernandez-Nuñez N, Makangara-Cigolo JC, Pratt C, Vakaniaki EH, Hoff NA, Luakanda-Ndelemo G, Akil-Bandali P, Nundu SS, Mulopo-Mukanya N, Ngimba M, Modadra-Madakpa[...]